Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM1 | Q13255 | 11/20 | 0.58 |
| ▸ | GRM5 | P41594 | 11/20 | 0.58 |
| ▸ | WNT3A | P56704 | 1/20 | 0.56 |
| ▸ | NAMPT | P43490 | 1/20 | 0.51 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.49 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.47 |
| ▸ | BTK | Q06187 | 1/20 | 0.47 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1199388 | 0.89 | NAMPT (0.59) | GRM1GRM5NAMPTPDK4TNK2 | |
| SCHEMBL2274299 | 0.86 | GPR119 (0.52) | GRM1GRM5WNT3ANAMPTPDK4 | |
| SCHEMBL4251822 | 0.84 | GRM5 (0.70) | GRM1GRM5WNT3ANAMPTPDK4 | |
| SCHEMBL29559340 | 0.84 | GRM5 (0.70) | GRM1GRM5WNT3ANAMPTPDK4 | |
| SCHEMBL7470566 | 0.84 | GRM5 (0.60) | GRM1GRM5NAMPTPDK4TNK2 | |
| SCHEMBL16340041 | 0.84 | GRM1 (0.57) | GRM1GRM5WNT3ANAMPTPDK4 | |
| SCHEMBL903903 | 0.83 | GRM1 (0.56) | GRM1GRM5WNT3ANAMPTPDK4 | |
| SCHEMBL18113625 | 0.83 | ALDH1A1 (0.49) | WNT3ANAMPT | |
| SCHEMBL13096687 | 0.82 | GRM1 (0.55) | GRM1GRM5WNT3ANAMPTPDK4 | |
| SCHEMBL31039781 | 0.82 | GRM1 (0.55) | GRM1GRM5WNT3ANAMPTPDK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107849053-B | Spiro compounds | 里科瑞尔姆IP控股有限责任公司 | 2020-10-30 | — | — | CN | disclosed |
| US-20200268714-A1 | SPIROCYCLIC COMPOUNDS | KALYRA PHARMACEUTICALS, INC. | 2020-08-27 | — | — | US | disclosed |
| EP-3277690-B1 | SPIROCYCLIC COMPOUNDS | RECURIUM IP HOLDINGS LLC (US) | 2020-02-26 | — | — | EP | disclosed |
| EP-3277690-B1 | SPIROCYCLIC COMPOUNDS | RECURIUM IP HOLDINGS LLC (US) | 2020-02-26 | — | — | EP | disclosed |
| US-20190201380-A1 | SPIROCYCLIC COMPOUNDS | KALYRA PHARMACEUTICALS, INC. | 2019-07-04 | — | — | US | disclosed |
| US-20190201380-A1 | SPIROCYCLIC COMPOUNDS | KALYRA PHARMACEUTICALS, INC. | 2019-07-04 | — | — | US | disclosed |
| US-20180207132-A1 | SPIROCYCLIC COMPOUNDS | RECURIUM IP HOLDINGS, LLC | 2018-07-26 | — | — | US | disclosed |
| US-20180207132-A1 | SPIROCYCLIC COMPOUNDS | RECURIUM IP HOLDINGS, LLC | 2018-07-26 | — | — | US | disclosed |
| US-20180207132-A1 | SPIROCYCLIC COMPOUNDS | RECURIUM IP HOLDINGS, LLC | 2018-07-26 | — | — | US | disclosed |
| EP-3277690-A1 | SPIROCYCLIC COMPOUNDS | Kalyra Pharmaceuticals, Inc. (US) | 2018-02-07 | — | — | EP | disclosed |
| US-20110038876-A1 | HETEROCYCLIC COMPOUNDS AND USE THEREOF AS ERK INHIBITORS | SCHERING CORPORATION | 2011-02-17 | — | — | US | disclosed |
| US-20110038876-A1 | HETEROCYCLIC COMPOUNDS AND USE THEREOF AS ERK INHIBITORS | SCHERING CORPORATION | 2011-02-17 | — | — | US | disclosed |
| US-20090118284-A1 | Novel compounds that are ERK inhibitors | MERCK SHARP & DOHME LLC | 2009-05-07 | — | — | US | disclosed |
| US-20090118284-A1 | Novel compounds that are ERK inhibitors | MERCK SHARP & DOHME LLC | 2009-05-07 | — | — | US | disclosed |
| US-20090118284-A1 | Novel compounds that are ERK inhibitors | MERCK SHARP & DOHME LLC | 2009-05-07 | — | — | US | disclosed |
| WO-2008156739-A1 | HETEROCYCLIC COMPOUNDS AND USE THEREOF AS ERK INHIBITORS | SCHERING CORPORATION (US) | 2008-12-24 | — | — | WO | disclosed |
| US-20070191604-A1 | Novel compounds that are ERK inhibitors | SCHERING CORPORATION | 2007-08-16 | — | — | US | disclosed |
| US-20070191604-A1 | Novel compounds that are ERK inhibitors | SCHERING CORPORATION | 2007-08-16 | — | — | US | disclosed |
| US-20070191604-A1 | Novel compounds that are ERK inhibitors | SCHERING CORPORATION | 2007-08-16 | — | — | US | disclosed |
| WO-2007070398-A1 | POLYCYCLIC INDAZOLE DERIVATIVES THAT ARE ERK INHIBITORS | SCHERING CORPORATION (US) | 2007-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110038876-A1 | HETEROCYCLIC COMPOUNDS AND USE THEREOF AS ERK INHIBITORS | MAPK1, MAPK4, MAPK10 | GRM1 3670/4885GRM5 4174/4885WNT3A 1997/4885 |
| US-20200268714-A1 | SPIROCYCLIC COMPOUNDS | PKD1, AR, PKD2 | GRM1 4102/4885GRM5 3424/4885WNT3A 3151/4885 |
| US-20090118284-A1 | Novel compounds that are ERK inhibitors | MAPK1, MAPK4, MAPK10 | GRM1 3394/4885GRM5 4034/4885WNT3A 2725/4885 |
| US-20070191604-A1 | Novel compounds that are ERK inhibitors | MAPK1, MAPK4, MAPKAPK2 | GRM1 3271/4885GRM5 3957/4885WNT3A 2614/4885 |
| US-20190201380-A1 | SPIROCYCLIC COMPOUNDS | PKD1, AR, PKD2 | GRM1 4102/4885GRM5 3424/4885WNT3A 3151/4885 |
| US-20180207132-A1 | SPIROCYCLIC COMPOUNDS | PKD1, AR, PKD2 | GRM1 4102/4885GRM5 3424/4885WNT3A 3151/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.